Jump to main content
Jump to site search

Issue 41, 2017
Previous Article Next Article

Synthesis and biological evaluation of novel teixobactin analogues

Author affiliations

Abstract

The cyclic depsipeptide, teixobactin, possesses promising activity against a range of antimicrobial-resistant (AMR) pathogenic bacteria, including Staphylococcus aureus and Mycobacterium tuberculosis. Teixobactin contains a number of non-canonical residues, including the synthetically challenging amino acid, L-allo-enduracididine, complicating clinical application of this peptide. Herein, we report the synthesis of six analogues of teixobactin, in which the non-canonical L-allo-enduracididine amino acid is replaced by isosteric, commercially available Fmoc-amino acid building blocks. Biological evaluation of the analogues has revealed promising activity, particularly for guanidine isosteres, against AMR strains of S. aureus and Enterococcus faecalis, highlighting the potential for this class of cyclic depsipeptides in the treatment of Gram-positive infections.

Graphical abstract: Synthesis and biological evaluation of novel teixobactin analogues

Back to tab navigation

Supplementary files

Publication details

The article was received on 30 Aug 2017, accepted on 03 Oct 2017 and first published on 04 Oct 2017


Article type: Paper
DOI: 10.1039/C7OB02169K
Citation: Org. Biomol. Chem., 2017,15, 8755-8760
  •   Request permissions

    Synthesis and biological evaluation of novel teixobactin analogues

    C. E. Schumacher, P. W. R. Harris, X. Ding, B. Krause, T. H. Wright, G. M. Cook, D. P. Furkert and M. A. Brimble, Org. Biomol. Chem., 2017, 15, 8755
    DOI: 10.1039/C7OB02169K

Search articles by author

Spotlight

Advertisements